BCRX vs HAE: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
HAE is the larger of the two ($5.48B market cap): the incumbent the market prices for continued execution (19.20x forward earnings, beta 0.59). BCRX is the smaller challenger ($1.87B), cheaper on forward earnings (8.51x): more room to run, but more to prove. If you believe in growth, HAE fits: analysts expect its revenue to rise 11% next year, against 2% for BCRX. If you believe in paying less for profit, BCRX fits: it trades at 8.51x forward earnings, against 19.2x for HAE.
BCRX vs HAE: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BCRX | HAE | What it tells you |
|---|---|---|---|
| Market cap | $1.87B | $5.48B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 8.51 | 19.20 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.51 | 0.59 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 21% of range | 86% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Reading it: BCRX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how BCRX and HAE affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BCRX and HAE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BCRX and HAE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does BioCryst Pharmaceuticals (BCRX) do?
BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases, with a near-total focus on hereditary angioedema (HAE), a genetic disorder that causes unpredictable and sometimes life-threatening swelling attacks. Its lead product is ORLADEYO (berotralstat), the first oral, once-daily plasma kallikrein inhibitor approved to prevent HAE attacks, which competes against injectable and infused prophylaxis therapies. The company also markets RAPIVAB (peramivir) for influenza and, through its January 2026 acquisition of Astria Therapeutics, added navenibart (formerly STAR-0215), a long-acting injectable antibody in Phase 3 for HAE prophylaxis, plus an early-stage ocular program (avoralstat).
What does Haemonetics (HAE) do?
Haemonetics Corporation, based in Boston and listed on the NYSE, has sold blood-handling technology since 1971. Its largest business is plasma: the NexSys PCS apheresis machines, and the far more profitable single-use disposable kits that run on them, sit in the collection centers operated by companies like Grifols, Takeda's BioLife and Octapharma, which turn donated plasma into immunoglobulin and other plasma-derived therapies. A second business, grouped under the hospital umbrella, splits into Interventional Technologies (the VASCADE and VASCADE MVP vascular closure devices used after catheter procedures, plus the OpSens optical pressure sensing line and the Attune Medical esophageal cooling device) and Blood Management Technologies (TEG viscoelastic hemostasis analyzers, Cell Saver autotransfusion systems, and blood-tracking software). A third and shrinking business supplies whole-blood and apheresis collection to blood banks.
BCRX vs HAE: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- BCRX drivers: ORLADEYO revenue growth and operating leverage; Navenibart and the Astria pipeline bet.
- HAE drivers: Plasma, and the return of CSL; Yield software as a razor-blade lever.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: BioCryst is a concentrated single-franchise story: the large majority of revenue comes from ORLADEYO, so any competitive share loss, pricing pressure, or safety signal would hit hard; reported ORLADEYO growth of only about 1% in Q2 2026 shows how quickly the trajectory can flatten. For HAE, customer concentration is the structural risk, and the CSL news cuts both ways: plasma collection in the United States is consolidated into a handful of buyers, the original CSL departure showed how much revenue a single non-renewal can remove, and the stock's ~60% one-year gain now assumes a CSL rollout whose scope and timing the company itself says could change.
BCRX or HAE: which should you pick?
If the story you believe is BCRX's (ORLADEYO revenue growth and operating leverage), BCRX is the more direct way to own it; if it is HAE's (Plasma, and the return of CSL), HAE is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BCRX and HAE guides.
BCRX vs HAE: the full fundamentals
BCRX. BioCryst trades on the strength and durability of its ORLADEYO franchise rather than on trailing GAAP earnings, which still show a net loss of about $360 million because of the roughly $698 million one-time acquired-IPR&D charge from the Astria deal in Q1 2026. Trailing revenue near $962 million is inflated by one-time licensing items, so the guided $625 to $645 million of 2026 revenue is the cleaner base, and analysts expect about $736 million in 2027. At $7.28 the stock trades near 8.5x forward earnings and about 5x EV/EBITDA, while the 11 analysts tracked by Yahoo Finance carry a mean target near $20.
HAE. The multiple re-rated from a little over three times sales in August to about four times, almost entirely on the CSL disclosure, and has held there since the November report. Trailing GAAP EPS of ~$2.26 is held down by charges, including a loss in the March 2026 quarter, while analysts expect ~$5.34 of adjusted EPS for fiscal 2027 and ~$6.27 for fiscal 2028, which puts the shares at ~19x the later year. Debt of ~$1.12 billion against ~$263 million of cash, with net leverage near 2.5x, sits alongside trailing free cash flow of ~$297 million.
Headline figures (approximate, November 2026): BCRX shows revenue (ttm) ~$962M (includes one-time licensing revenue), q3 2026 total revenue ~$180M (up ~13% YoY; ~$166M estimate), q3 2026 eps Adjusted $0.27 vs $0.12 estimate; GAAP $0.14 diluted, 2026 revenue guidance ~$625M to $645M, upper end expected; HAE shows market cap ~$5.5B, share price (nov 20, 2026) ~$120.36, revenue (ttm) ~$1.38B, up ~9% in the latest quarter, q2 fy2027 (quarter ended sept 2026) ~$358M revenue, ~10% organic growth; adj. EPS ~$1.35 vs ~$1.29 est..
The bottom line: BCRX vs HAE
BCRX and HAE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BCRX and HAE exposure against your real portfolio. It is not an investment adviser.
Wondering how BCRX or HAE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about BioCryst Pharmaceuticals
Ask Walnut's AI anything about BCRX and see how it fits what you own.
FAQ
What is the difference between BCRX and HAE?
+
BioCryst Pharmaceuticals develops and commercializes medicines for rare diseases, with a near-total focus on hereditary angioedema (HAE), a genetic disorder that causes unpredictable and sometimes life-threatening swelling attacks. Haemonetics Corporation, based in Boston and listed on the NYSE, has sold blood-handling technology since 1971. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BCRX or HAE the better stock?
+
Neither is universally better. HAE is the larger incumbent; BCRX is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BCRX or HAE?
+
On forward P/E (as of November 2026), BCRX trades at 8.51x and HAE at 19.20x, so BCRX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BCRX and HAE?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BCRX vs HAE?
+
BCRX: BioCryst is a concentrated single-franchise story: the large majority of revenue comes from ORLADEYO, so any competitive share loss, pricing pressure, or safety signal would hit hard; reported ORLADEYO growth of only about 1% in Q2 2026 shows how quickly the trajectory can flatten. The HAE prophylaxis market is crowding fast, with Takeda's Takhzyro, CSL's Andembry, and Ionis's Dawnzera (donidalorsen) all competing for the same patients on convenience and dosing frequency. The Astria acquisition added debt (including a Blackstone financing facility; total debt was about $828 million against about $375 million of cash as of September 30, 2026) and share dilution, and navenibart still carries clinical and regulatory risk with Phase 3 data expected in the third quarter of 2027 and a filing only around the end of 2027. GAAP results have been distorted by large non-cash charges, and the company has a history of operating losses, so profitability at the GAAP level is not yet proven. As a biotech, it remains sensitive to trial outcomes, regulatory decisions, and financing conditions. The share price has also fallen about 26% in three months despite beats, and Wedbush trimmed its target to $17 from $18 on November 4, 2026, so sentiment can move independently of reported results. HAE: Customer concentration is the structural risk, and the CSL news cuts both ways: plasma collection in the United States is consolidated into a handful of buyers, the original CSL departure showed how much revenue a single non-renewal can remove, and the stock's ~60% one-year gain now assumes a CSL rollout whose scope and timing the company itself says could change. The contract's pricing was not disclosed on the November 2026 call, management cut its expected margin expansion for fiscal 2027 to 0 to 50 basis points, and capital spending will be elevated for two years to support the ramp. The September quarter's gross margin also included about 200 basis points of tariff refunds that will not recur. Immunoglobulin demand has been reliable but is not guaranteed, and any move by a large customer toward in-house or competing collection hardware would repeat the problem. The interventional portfolio was assembled through three acquisitions in roughly two years, which leaves goodwill and intangibles on the balance sheet and about $1.12 billion of debt against them, and the pulsed field ablation transition has already demonstrated that a procedure-mix shift can cut into those products faster than the thesis assumed. The blood center business continues to decline as hospitals use less transfused blood, so mix has to keep improving just to hold consolidated growth flat. Tariffs, medical-device quality regulation and the pace of hospital capital budgets are the usual additional constraints on a company that manufactures physical disposables at scale.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BCRX or HAE; figures are approximate and dated (as of November 2026). Verify current data before investing.